Literature DB >> 20434787

X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Yang Liu1, Lizhong Wang, Pan Zheng.   

Abstract

Unlike autosomal genes, the majority of X-linked genes are subject to dosage compensation. As a result, female tissues comprise cells exclusively expressing X-linked genes from one or other parent. The implication of having only one allele of active X-linked genes in cancer pathogenesis, i.e. somatic single-hit inactivation and dominant inheritance, has not been extensively explored. Recent studies have identified FOXP3 and WTX as two X-linked tumor suppressor genes that are somatically inactivated by single genetic hits. Because the predicted dominant inheritance of cancer risk has not been demonstrated in humans, we will discuss the possible conditions that might prevent such dominant inheritance. We also argue that the existence of a genetically intact allele in cancer cells in women, together with apparent abnormal X inactivation in cancer cells, might provide an opportunity to selectively reactivate tumor suppressor genes for cancer therapy. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434787      PMCID: PMC2901104          DOI: 10.1016/j.tig.2010.03.004

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  50 in total

1.  Confirmation of the prostate cancer susceptibility locus HPCX in a set of 104 German prostate cancer families.

Authors:  Sylvia Bochum; Thomas Paiss; Walther Vogel; Kathleen Herkommer; Richard Hautmann; Juergen Haeussler
Journal:  Prostate       Date:  2002-06-01       Impact factor: 4.104

Review 2.  X-chromosome genetics and human cancer.

Authors:  Alain Spatz; Christophe Borg; Jean Feunteun
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

3.  Evidence of an X-linked or recessive genetic component to prostate cancer risk.

Authors:  K R Monroe; M C Yu; L N Kolonel; G A Coetzee; L R Wilkens; R K Ross; B E Henderson
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

4.  The impact of family history on early detection of prostate cancer.

Authors:  S A Narod; A Dupont; L Cusan; P Diamond; J L Gomez; R Suburu; F Labrie
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

5.  Documentation of Burkitt lymphoma with t(8;14) (q24;q32) in X-linked lymphoproliferative disease.

Authors:  R M Egeler; J de Kraker; R Slater; D T Purtilo
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

6.  Xist-deficient mice are defective in dosage compensation but not spermatogenesis.

Authors:  Y Marahrens; B Panning; J Dausman; W Strauss; R Jaenisch
Journal:  Genes Dev       Date:  1997-01-15       Impact factor: 11.361

7.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome.

Authors:  G Pilia; R M Hughes-Benzie; A MacKenzie; P Baybayan; E Y Chen; R Huber; G Neri; A Cao; A Forabosco; D Schlessinger
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

8.  Evidence for a prostate cancer susceptibility locus on the X chromosome.

Authors:  J Xu; D Meyers; D Freije; S Isaacs; K Wiley; D Nusskern; C Ewing; E Wilkens; P Bujnovszky; G S Bova; P Walsh; W Isaacs; J Schleutker; M Matikainen; T Tammela; T Visakorpi; O P Kallioniemi; R Berry; D Schaid; A French; S McDonnell; J Schroeder; M Blute; S Thibodeau; H Grönberg; M Emanuelsson; J E Damber; A Bergh; B A Jonsson; J Smith; J Bailey-Wilson; J Carpten; D Stephan; E Gillanders; I Amundson; T Kainu; D Freas-Lutz; A Baffoe-Bonnie; A Van Aucken; R Sood; F Collins; M Brownstein; J Trent
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

9.  Familial testicular cancer in Norway and southern Sweden.

Authors:  K Heimdal; H Olsson; S Tretli; P Flodgren; A L Børresen; S D Fossa
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

10.  Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci.

Authors:  W M Brown; E M Lange; H Chen; S L Zheng; B Chang; K E Wiley; S D Isaacs; P C Walsh; W B Isaacs; J Xu; K A Cooney
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more
  16 in total

1.  Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers.

Authors:  Weiquan Li; Lizhong Wang; Hiroto Katoh; Runhua Liu; Pan Zheng; Yang Liu
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

2.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

Review 3.  Signalling through FOXP3 as an X-linked tumor suppressor.

Authors:  Hiroto Katoh; Pan Zheng; Yang Liu
Journal:  Int J Biochem Cell Biol       Date:  2010-08-01       Impact factor: 5.085

4.  FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1.

Authors:  Hiroto Katoh; Zhaohui S Qin; Runhua Liu; Lizhong Wang; Weiquan Li; Xiangzhi Li; Lipeng Wu; Zhanwen Du; Robert Lyons; Chang-Gong Liu; Xiuping Liu; Yali Dou; Pan Zheng; Yang Liu
Journal:  Mol Cell       Date:  2011-12-09       Impact factor: 17.970

Review 5.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

Review 6.  Deciphering the Role of the Barr Body in Malignancy: An insight into head and neck cancer.

Authors:  Deepti Sharma; George Koshy; Shruti Gupta; Bhushan Sharma; Sonal Grover
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

7.  FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1.

Authors:  Weiquan Li; Hiroto Katoh; Lizhong Wang; Xiaochun Yu; Zhanwen Du; Xiaoli Yan; Pan Zheng; Yang Liu
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

Review 8.  FOXP3: genetic and epigenetic implications for autoimmunity.

Authors:  Hiroto Katoh; Pan Zheng; Yang Liu
Journal:  J Autoimmun       Date:  2013-01-11       Impact factor: 7.094

Review 9.  Guided by RNAs: X-inactivation as a model for lncRNA function.

Authors:  John E Froberg; Lin Yang; Jeannie T Lee
Journal:  J Mol Biol       Date:  2013-06-28       Impact factor: 5.469

10.  The X-linked tumor suppressor TSPX interacts and promotes degradation of the hepatitis B viral protein HBx via the proteasome pathway.

Authors:  Tatsuo Kido; Jing-Hsiung James Ou; Yun-Fai Chris Lau
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.